⌕
Lexicon Pharmaceuticals · LXRX · Nasdaq
Tenet 41 · Weak
Compare
$1.78+1.71%At closeTenet 41 · Weak
$1.78+0.03 (+1.71%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Lexicon Pharmaceuticals (LXRX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

55 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~369.2%/yr (FY21→FY25), net margin −34.9%. Worth your attention in FY25: Share count (+149.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
144.4
no value for 1 of 5 yearsCAGR —
Net income ($M)—
−50.3
no value for 1 of 5 yearsCAGR —
Free cash flow ($M)▲62.3%
−67.9
FY21→FY25CAGR —
Diluted EPS—
−0.14
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+149.3%

145.7mn → 363.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$0.0K

−100.0% YoY in FY25 · 0.0% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)144450.0Revenue−274.0COGS−61121.0R&D−45658.0SG&A−48911.0Op income−1430.0Tax & other−50341.0Net income

-35¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -34.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
133,184.0144,450.0—A1,204.0139.0298.0——
Cost of revenue
427.0274.0—A85.00.00.0——
Gross profit
132,757.0—B—A1,119.0—C—C——
Research & development
57,717.061,121.0—A58,887.052,816.055,046.0——
Selling, general & admin
45,544.045,658.0—A113,982.048,083.032,342.0——
Total operating expenses
201,975.0205,493.0—A172,869.0100,899.087,388.0——
Operating incomefeeds ROC rank
−56,812.0−48,911.0—A−171,750.0−100,760.0−87,090.0——
Other income, net
−9,451.0−5,341.0—A−5,369.0−2,780.0134.0——
Pretax income
−66,263.0−54,252.0—A−177,119.0−103,540.0−86,956.0——
Income tax
———A—————
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−62,352.0−50,341.0—A−177,119.0−101,944.0−87,758.0——
Per share
Diluted EPSbuyback-sensitive
−0.14−0.14—A−0.80−0.62−0.60——
Diluted shares (mn)
444.96363.05—A221.13165.73145.65——
Margins
Gross margin99th pct in Healthcare
99.7%—B—A92.9%—C—C——
Operating margin
−42.7%−33.9%—A−14265.0%−72489.2%−29224.8%——
Net margin17th pct in Healthcare
−46.8%−34.9%—A−14710.9%−73341.0%−29449.0%——
† TTM = trailing four quarters through 2026-09-30.A Withheld by our checks.B Withheld: this year's gross margin is not on the same cost basis as the earlier years.C Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Lexicon Pharmaceuticals' net income?

Lexicon Pharmaceuticals reported net income of −$50.3M in fiscal 2025, a net margin of −34.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.